Light4Sight SIGNED
Light-activated carriers for the controlled delivery of therapeutic peptides in posterior segment eye diseases
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Light4Sight project word cloud
Explore the words cloud of the Light4Sight project. It provides you a very rough idea of what is the project "Light4Sight" about.
Project "Light4Sight" data sheet
The following table provides information about the project.
| Coordinator |
QUEEN MARY UNIVERSITY OF LONDON
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 224˙933 € |
| EC max contribution | 224˙933 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2018 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-11-01 to 2021-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | QUEEN MARY UNIVERSITY OF LONDON | UK (LONDON) | coordinator | 224˙933.00 |
Map
Project objective
In 2016, the global sales of biopharmaceutical drugs (protein, peptides) in ophthalmic applications exceeded $8 billion and is estimated to increase to $35.7 billion by 2025. The growth of the ophthalmic drug market is primarily driven by an increasing aged population suffering from age- and lifestyle-related diseases such as macular degeneration, diabetic retinopathy, glaucoma, among others. These diseases cause moderate or complete vision loss, resulting in significant reduction in quality of life. Consequently, innovative approaches for the effective delivery of biopharmaceuticals for the treatment of chronic intraocular diseases are required. Currently, intravitreal injection of drugs is the most acceptable and effective method to treat vitreoretinal diseases. By placing the drug in the posterior eye, it evades the ocular barriers common in topical and systemic delivery, allowing higher drug doses to reach the target site. However, treatments require frequent injections to maintain adequate intraocular concentration, which are invasive, increase the risk of adverse effects and pose significant treatment burden on patients and healthcare providers. Thus, alternative ways to deliver these drugs that require less frequent administration need to be developed. Light4Sight aims to develop a novel delivery platform consisting of self-assembling nanocarriers incorporating therapeutic peptides and suspended within a light-sensitive supramolecular hydrogel. The hydrogel can be injected in the vitreous and release of nanocarriers be activated through the irradiation of visible light. This approach provides several benefits: 1) minimizes the use of repeated injections reducing treatment burden; 2) reduces burst release of the nanocarriers avoiding potential dose related toxicity; 3) on-demand release to match patient needs; 4) allows high drug loading for long-term therapy; 5) protects peptide drugs from rapid clearance in the vitreous increasing their half-life.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIGHT4SIGHT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LIGHT4SIGHT" are provided by the European Opendata Portal: CORDIS opendata.